Erythropoiesis Stimulating Agent (ESA) use, by DOPPS country and cross-section

  N Ptnts Total N Wgtd %
DOPPS Country DOPPS Cross-section 448 510 87.4%
AusNZ D2(2002)
D3(2006) 475 518 91.0%
D3(2007) 432 480 89.7%
D4(2010) 247 280 87.1%
D4(2011) 336 388 87.1%
Belgium D2(2002) 508 537 94.8%
D3(2006) 480 499 96.3%
D3(2007) 390 411 95.3%
D4(2010) 422 441 95.6%
D4(2011) 405 430 94.1%
Canada D2(2002) 544 585 92.1%
D3(2006) 519 544 95.3%
D3(2007) 421 441 93.6%
D4(2010) 299 326 91.7%
D4(2011) 408 446 91.9%
France D2(2002) 435 508 85.8%
D3(2006) 510 549 92.9%
D3(2007) 504 543 93.1%
D4(2010) 323 366 89.1%
D4(2011) 395 449 87.8%
Germany D2(2002) 497 563 88.0%
D3(2006) 514 573 89.3%
D3(2007) 567 622 90.5%
D4(2010) 517 576 89.0%
D4(2011) 547 612 89.4%
Italy D2(2002) 504 572 87.0%
D3(2006) 460 518 88.4%
D3(2007) 472 541 86.5%
D4(2010) 473 531 89.2%
D4(2011) 492 561 88.0%
Japan D2(2002) 1,472 1,763 82.1%
D3(2006) 1,531 1,824 82.8%
D3(2007) 1,548 1,847 83.6%
D4(2010) 1,400 1,595 87.2%
D4(2011) 1,465 1,635 89.2%
Spain D2(2002) 570 605 93.9%
D3(2006) 618 662 93.7%
D3(2007) 513 551 93.6%
D4(2010) 549 610 90.1%
D4(2011) 506 555 90.6%
Sweden D2(2002) 515 545 95.1%
D3(2006) 515 537 96.2%
D3(2007) 480 509 94.6%
D4(2010) 396 434 91.0%
D4(2011) 419 472 88.9%
UK D2(2002) 527 555 95.1%
D3(2006) 407 437 93.1%
D3(2007) 326 349 94.7%
D4(2010) 318 354 90.3%
D4(2011) 383 428 89.0%
US D2(2002) 2,054 2,238 91.9%
D3(2006) 1,677 1,805 93.5%
D3(2007) 1,235 1,316 94.3%
D4(2010) 3,110 3,267 95.5%
D4(2011) 3,401 3,649 93.6%

Any ESA prescription in previous three months, among all patients

Please see additional methodological information in the Data Sources and Methods section.